8-KEarnings & ResultsExhibits & Filings

QUEST DIAGNOSTICS INC 8-K Report, Financial Results (Feb 1, 2018)

Filed February 1, 2018For Securities:DGX

Summary

Quest Diagnostics (DGX) filed an 8-K on February 1, 2018, to announce its financial results for the fourth quarter and full year ended December 31, 2017. The report primarily references a press release attached as an exhibit, which details the company's performance. Investors should review this press release for specific operational and financial metrics released on that date. While the 8-K itself is brief and refers to the press release for details, it signals the official disclosure of the company's performance for the period. Key information likely includes revenue, earnings per share (EPS), and any forward-looking guidance provided by management. Investors will want to scrutinize these numbers against expectations and prior periods to assess the company's trajectory and the effectiveness of its business strategies.

Key Highlights

  • 1Quest Diagnostics (DGX) announced its Q4 and full-year 2017 financial results on February 1, 2018, via an 8-K filing.
  • 2The 8-K filing primarily incorporates by reference a press release detailing these results.
  • 3Investors need to consult Exhibit 99.1 (the press release) for the specific financial and operational data.
  • 4The filing covers the performance period ending December 31, 2017.
  • 5This disclosure is a standard regulatory event providing an update on the company's financial condition and results of operations.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially announce and report Quest Diagnostics' financial results for the fourth quarter and the full fiscal year ended December 31, 2017, as per SEC regulations.

The detailed financial results are not fully provided within the 8-K itself. They are contained within the press release attached as Exhibit 99.1 to the 8-K filing. Investors should refer to this press release for specific figures like revenue, net income, EPS, and any management commentary.

These results cover the financial performance of Quest Diagnostics for the three months ended December 31, 2017 (the fourth quarter) and the twelve months ended December 31, 2017 (the full fiscal year).

This specific 8-K filing (Item 2.02) is primarily focused on announcing financial results. While the accompanying press release may contain some strategic commentary, the 8-K itself does not typically detail new material events like mergers, acquisitions, or executive changes unless they are directly tied to the financial results being announced.